Textiles & Apparel Global On demand · 24-48h

Global Class I Compression Garments and Stockings Market Strategic Research Report

Global Class I Compression Garments and Stockings Market Str…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Class I Compression Garments and Stockings Market
$1.86B2025
7%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Compression Garments, Compression Stockings

By Application: Online Sales, Clinics, Outpatient Surgery Centers, Hospitals and Other Medical Institutions, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Medical Z, Nouvelle Inc., Leonisa Inc., Santemol Group Medikal, 2XU Pty Ltd., Therafirm, SIGVARIS, Medi GmbH & Co. KG, BSN Medical, 3M, Covidien Ltd.

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 112 pages
Market size 2025
$1.86B
Billion USD
Forecast CAGR
7%
2025-2032
Forecast 2032
$3B
Projected
Regiones
5
Asia Pacific · Latin America · MEA · Europe · North America

Vista general

Scope of the Report

The global Class I Compression Garments and Stockings market size is predicted to grow from US$ 1,859 million in 2025 to US$ 2,968 million in 2032; it is expected to grow at a CAGR of 7.0% from 2026 to 2032.

In 2025, global production of Class I compression garments and stockings reached approximately 67.9 million units, based on an average market price of around US$ 28 per unit. Industry gross profit margins generally ranged from 40% to 60%, reflecting value added from textile engineering, medical-grade materials, and standardized pressure control. Global production capacity in 2025 was estimated at about 84.9 million units, indicating sufficient supply capability to support growing demand from preventive healthcare and early-stage venous care.

Class I compression garments and stockings are medical textiles designed to provide mild, graduated compression to the limbs, typically used for early-stage venous disorders, fatigue relief, and preventive care. They apply controlled pressure to improve blood circulation while maintaining comfort for long-term daily wear.

The industrial chain includes upstream elastic yarns, medical textiles, dyes, and finishing chemicals. The midstream focuses on knitting, pressure calibration, shaping, and quality inspection. Downstream applications mainly involve hospitals, pharmacies, rehabilitation centers, and direct-to-consumer healthcare channels.

Global key Class I Compression Garments and Stockings players cover Medical Z, Nouvelle Inc., Leonisa Inc., Santemol Group Medikal, 2XU Pty Ltd., etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Class I Compression Garments and Stockings market?

What factors are driving Class I Compression Garments and Stockings market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Class I Compression Garments and Stockings market opportunities vary by end market size?

How does Class I Compression Garments and Stockings break out by Type, by Application?

This report presents a comprehensive overview of the global Class I Compression Garments and Stockings market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Compression Garments
  • Compression Stockings

Segment by Length & Coverage

  • Knee-High Compression Garments
  • Thigh-High Compression Garments

Segment by Application

  • Online Sales
  • Clinics
  • Outpatient Surgery Centers
  • Hospitals and Other Medical Institutions
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Class I Compression Garments and Stockings market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Online Sales, Clinics, Outpatient Surgery Centers evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Class I Compression Garments and Stockings Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 7%
Regional growth momentum
Market share by segment
Key metrics
Base value
$1.86B
2025
Forecast
$3B
2032
CAGR
7%
2025–2032
Regiones
5
global
Key companies
Medical ZNouvelle Inc.Leonisa Inc.Santemol Group Medikal2XU Pty Ltd.TherafirmSIGVARISMedi GmbH & Co. KG
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Compression GarmentsCompression Stockings
By Application
Online SalesClinicsOutpatient Surgery CentersHospitals and Other Medical InstitutionsOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Compression Garments
  • 3.1.3 Compression Stockings
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Online Sales
  • 4.1.3 Clinics
  • 4.1.4 Outpatient Surgery Centers
  • 4.1.5 Hospitals and Other Medical Institutions
  • 4.1.6 Others
  • 4.1.7 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Medical Z
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Nouvelle Inc.
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Leonisa Inc.
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Santemol Group Medikal
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 2XU Pty Ltd.
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Therafirm
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 SIGVARIS
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Medi GmbH & Co. KG
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 BSN Medical
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 3M
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Covidien Ltd.
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Class I Compression Garments and Stockings market?
The global Class I Compression Garments and Stockings market is estimated at US$ 1.86 billion in 2025 (base year) and is projected to reach US$ 2.97 billion by 2032.
How fast is the Class I Compression Garments and Stockings market expected to grow?
The market is expected to grow at a CAGR of 7.0% from 2026 to 2032, expanding from US$ 1.86 billion in 2025 to US$ 2.97 billion in 2032, roughly 1.6 times its base-year value.
What does the Class I Compression Garments and Stockings market cover?
In 2025, global production of Class I compression garments and stockings reached approximately 67.9 million units, based on an average market price of around US$ 28 per unit. Industry gross profit margins generally ranged from 40% to 60%, reflecting value added from textile engineering, medical-grade materials, and standardized pressure control. Global production capacity in 2025 was estimated at about 84.9 million units, indicating sufficient supply capability to support growing demand from preventive healthcare and early-stage venous care.
What are the main segments of the Class I Compression Garments and Stockings market by type?
By type, the market is segmented into Compression Garments and Compression Stockings.
Which applications drive demand in the Class I Compression Garments and Stockings market?
Key applications covered include Online Sales, Clinics, Outpatient Surgery Centers, Hospitals and Other Medical Institutions and Others.
Who are the key players in the Class I Compression Garments and Stockings market?
Key players profiled include Medical Z, Nouvelle Inc., Leonisa Inc., Santemol Group Medikal, 2XU Pty Ltd., Therafirm, SIGVARIS and Medi GmbH & Co. KG, among 11 companies covered in total.
Which regions and countries are covered for Class I Compression Garments and Stockings?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Class I Compression Garments and Stockings market?
What factors are driving Class I Compression Garments and Stockings market growth, globally and by region?
Who should buy the Class I Compression Garments and Stockings market report?
The report is intended for manufacturers and solution providers, distributors and end users in Online Sales, Clinics and Outpatient Surgery Centers, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Class I Compression Garments and Stockings market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from 3.500,00 US$
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.